U.S. Reps. Jack Bergman (R-Mich.) and Donald Davis' (D-N.C.) Sept. 17 resolution stated that FQHCs “should continue to operate under their longstanding, single patient definition for all services, including drugs purchased under the 340B drug pricing program.”
Ge Bai, a 340B critic, addresses the U.S. Senate Finance Committee during a hearing on her nomination for HHS assistant secretary for planning and evaluation.
